| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Manidipa Banerjee | |
| Debajit Dey | |||
| P2860 | cites work | Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus | Q21128797 |
| A very late viral protein triggers the lytic release of SV40 | Q21559509 | ||
| Hepatitis B virus replication | Q24563894 | ||
| Hepatitis B: the virus and disease | Q24642704 | ||
| Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors | Q24652511 | ||
| Progress and Prospects of Anti-HBV Gene Therapy Development | Q26799228 | ||
| Alphavirus 6K proteins form ion channels | Q44135119 | ||
| Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. | Q45217971 | ||
| Homology model and potential virus-capsid binding site of a putative HEV receptor Grp78. | Q45273095 | ||
| Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection | Q45402345 | ||
| Vertical transmission of hepatitis E virus | Q45786178 | ||
| Identification and site-directed mutagenesis of the primary (2A/2B) cleavage site of the hepatitis A virus polyprotein: functional impact on the infectivity of HAV RNA transcripts | Q45790633 | ||
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. | Q46575199 | ||
| Treatment of severe acute hepatitis E by ribavirin. | Q50555678 | ||
| Brief communication: case reports of ribavirin treatment for chronic hepatitis E. | Q50559518 | ||
| Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. | Q50582782 | ||
| Protection against hepatitis A by an inactivated vaccine | Q56995443 | ||
| A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children | Q57111592 | ||
| Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results | Q57791894 | ||
| EASL Recommendations on Treatment of Hepatitis C 2015 | Q58324800 | ||
| Surveillance for acute viral hepatitis--United States, 2006 | Q64126985 | ||
| Viral hepatitis: progress and promise | Q84418491 | ||
| In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L. | Q38976804 | ||
| β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity | Q39135630 | ||
| Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation | Q39340555 | ||
| Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. | Q39448952 | ||
| Treatment options for hepatitis delta virus infection | Q39502937 | ||
| Phenylpropenamide derivatives: anti-hepatitis B virus activity of the Z isomer, SAR and the search for novel analogs | Q39518117 | ||
| A Proapoptotic Peptide Derived from Reovirus Outer Capsid Protein μ1 Has Membrane-Destabilizing Activity | Q39627844 | ||
| Role of heat-shock protein 90 in hepatitis E virus capsid trafficking | Q39729370 | ||
| Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation | Q39746875 | ||
| Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection | Q39790232 | ||
| Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans | Q39823787 | ||
| Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus. | Q40042957 | ||
| Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles | Q40104711 | ||
| Infectious bursal disease virus, a non-enveloped virus, possesses a capsid-associated peptide that deforms and perforates biological membranes | Q40135132 | ||
| Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. | Q40633768 | ||
| Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy | Q40676324 | ||
| Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. | Q41633369 | ||
| The VP4 peptide of hepatitis A virus ruptures membranes through formation of discrete pores | Q41790424 | ||
| Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. | Q42274044 | ||
| Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 | ||
| Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection | Q42938081 | ||
| Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation | Q43166681 | ||
| Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
| Safety and Immunogenicity of a Live Attenuated Hepatitis A Virus Vaccine in Seronegative Volunteers | Q44080514 | ||
| The elusive function of the hepatitis C virus p7 protein | Q27026459 | ||
| Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons | Q27473471 | ||
| Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics | Q27489037 | ||
| Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid | Q27734262 | ||
| HIV protease inhibitors: a review of molecular selectivity and toxicity | Q28082749 | ||
| In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease | Q28343611 | ||
| DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A | Q28748683 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Evolution and classification of the CRISPR-Cas systems | Q29616645 | ||
| Structure, regulation and function of NF-kappa B | Q29620225 | ||
| Human membrane protein Tim-3 facilitates hepatitis A virus entry into target cells | Q33242928 | ||
| Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults | Q33460754 | ||
| Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts | Q33608244 | ||
| The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. | Q33647793 | ||
| Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. | Q33816313 | ||
| Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction | Q33836467 | ||
| Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. | Q33931634 | ||
| Homologous sequences in non-structural proteins from cowpea mosaic virus and picornaviruses | Q33939451 | ||
| The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells | Q34043221 | ||
| Molecular virology of hepatitis E virus | Q34166393 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 | ||
| Viroporins. | Q34230206 | ||
| The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. | Q34318146 | ||
| Analysis of deletion mutants indicates that the 2A polypeptide of hepatitis A virus participates in virion morphogenesis | Q34343028 | ||
| Oligomerization state and supramolecular structure of the HIV‐1 Vpu protein transmembrane segment in phospholipid bilayers | Q34389186 | ||
| Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators | Q34414171 | ||
| The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo | Q34459390 | ||
| Molecular biology and replication of hepatitis E virus | Q34479052 | ||
| The M2 proton channels of influenza A and B viruses | Q34483647 | ||
| AASLD guidelines for treatment of chronic hepatitis B. | Q34501660 | ||
| Proteoglycans act as cellular hepatitis delta virus attachment receptors | Q34625734 | ||
| Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids | Q34663350 | ||
| An overview of HCV molecular biology, replication and immune responses | Q34916120 | ||
| Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release | Q35033777 | ||
| Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity | Q35105877 | ||
| A review of hepatitis B vaccination | Q35194402 | ||
| Possible function for virus encoded K+ channel Kcv in the replication of chlorella virus PBCV-1. | Q35217943 | ||
| Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection | Q35839139 | ||
| Maternal-Fetal Hepatitis E Transmission: Is It Underestimated? | Q35905989 | ||
| Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase. | Q36088575 | ||
| The C-terminal region of the non-structural protein 2B from Hepatitis A Virus demonstrates lipid-specific viroporin-like activity | Q36227103 | ||
| Hepatitis A virus: from discovery to vaccines | Q36382222 | ||
| Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. | Q36428213 | ||
| Hepatitis C virus entry: molecular biology and clinical implications | Q36581588 | ||
| Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection | Q36883851 | ||
| Hepatitis C virus entry into host cells | Q36959983 | ||
| Current management of hepatitis B virus infection before and after liver transplantation | Q37556630 | ||
| An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases | Q37562042 | ||
| The minimalist architectures of viroporins and their therapeutic implications. | Q37619619 | ||
| The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. | Q37656511 | ||
| Management of acute hepatitis B. | Q37685609 | ||
| Hepatitis B virus: from diagnosis to treatment | Q37767858 | ||
| Pathogenesis and treatment of hepatitis e virus infection | Q38005798 | ||
| The coronavirus E protein: assembly and beyond | Q38010442 | ||
| New therapeutic strategies in HCV: polymerase inhibitors | Q38071392 | ||
| Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. | Q38110693 | ||
| The molecular virology of hepatitis B virus | Q38113177 | ||
| Life cycle and pathogenesis of hepatitis D virus: A review | Q38177275 | ||
| Hepatocellular carcinoma review: current treatment, and evidence-based medicine | Q38207012 | ||
| Lipid interactions during virus entry and infection | Q38240675 | ||
| Viroporins: structure, function and potential as antiviral targets | Q38507132 | ||
| Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. | Q38541054 | ||
| The future of antivirals: broad-spectrum inhibitors | Q38622424 | ||
| Systemic viral infections and collateral damage in the liver. | Q38622954 | ||
| Membrane integration of poliovirus 2B viroporin. | Q38725275 | ||
| The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity | Q38833969 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | viral hepatitis | Q1983841 |
| P304 | page(s) | 248-257 | |
| P577 | publication date | 2016-09-28 | |
| P1433 | published in | Journal of clinical and translational hepatology | Q27726496 |
| P1476 | title | Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis | |
| P478 | volume | 4 |
Search more.